Illumina Inc ILMN:NASDAQ

Last Price$286.17NASDAQ Previous Close - Last Trade as of 3:59PM ET 8/16/19

Today's Change+1.40(0.49%)
Bid (Size)$286.00 (15)
Ask (Size)$286.12 (1)
Day Low / High$285.49 - 291.36
Volume926.7 K

View Biotechnology IndustryPeer Comparison as of 08/16/2019


Illumina Inc ( NASDAQ )

Price: $286.17
Change: +1.40 (0.49%)
Volume: 926.7 K
3:59PM ET 8/16/2019

Biogen Inc ( NASDAQ )

Price: $231.68
Change: +4.05 (1.78%)
Volume: 1.1 M
3:59PM ET 8/16/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

Vertex Pharmaceuticals Inc ( NASDAQ )

Price: $184.94
Change: +3.82 (2.11%)
Volume: 1.3 M
4:00PM ET 8/16/2019

Regeneron Pharmaceuticals Inc ( NASDAQ )

Price: $296.85
Change: +3.74 (1.28%)
Volume: 742.6 K
4:00PM ET 8/16/2019

Read more news Recent News

Insider Trends: Illumina Insider Continues 90-Day Selling Trend
6:32PM ET 8/15/2019 MT Newswires

Jay T Flatley, Director, reported a sale of 3,300 shares in Illumina (ILMN) on Aug 14, 2019, for $951,588. Following the Form 4 filing with the SEC,...

Insider Trends: Insider Sales Continue 90-Day Trend at Illumina
4:12PM ET 8/13/2019 MT Newswires

Omead Ostadan, SVP Mktg, Prod & Strat Plan, sold 1,260 shares of Illumina (ILMN) on Aug 09, 2019, for $376,160. Ostadan, subsequent to the transactions...

Insider Trends: 90-Day Insider Selling Trend Prolonged at Illumina
5:25PM ET 8/12/2019 MT Newswires

Robert P Ragusa, SVP, Global Quality & Ops, on Aug 08, 2019, sold 2,230 shares in Illumina (ILMN) for $653,591. Ragusa, subsequent to the transactions...

Insider Trends: Illumina Insider Extends 90-Day Selling Trend
4:48PM ET 8/05/2019 MT Newswires

Francis A deSouza, Director and President & CEO, on Aug 01, 2019, sold 3,000 shares in Illumina (ILMN) for $903,759. Subsequent to the Form 4 filing with...

Company Profile

Business DescriptionIllumina, Inc. engages in the development and manufacture of integrated systems for the analysis of genetic variation and function. It operates through the Core Illumina and Consolidated Variable Interest Entity segments (VIE). The Core Illumina segments serve customers in the research, clinical and applied markets, and enable the adoption of genomic solutions. The Consolidated VIE segment includes activities of GRAIL and Helix. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA. View company web site for more details
Address5200 Illumina Way
San Diego, California 92122
Number of Employees7,300
Recent SEC Filing08/15/20194
President, Chief Executive Officer & DirectorFrancis A. deSouza
Senior Vice President-Global Quality & OperationsRobert P. Ragusa
Chief Financial Officer & Senior Vice PresidentSam A. Samad
Chief Technology Officer & Senior Vice PresidentMostafa Ronaghi

Company Highlights

Price Open$288.17
Previous Close$284.77
52 Week Range$268.62 - 380.76
Market Capitalization$42.1 B
Shares Outstanding147.0 M
SectorHealth Technology
Next Earnings Announcement10/22/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings45.42
Earnings per Share$5.72
Beta vs. S&P 500N/A
Revenue$3.3 B
Net Profit Margin27.56%
Return on Equity24.09%

Analyst Ratings as of 08/09/2019

Consensus RecommendationConsensus Icon
Powered by Factset